

PRESS RELEASE

For immediate release

RxVigilance: Major Update to Pregnancy and Breastfeeding Content.

Enhanced through an agreement with the publisher of the internationally recognized reference, Briggs Drugs in Pregnancy and Lactation.

Repentigny, February 5, 2026 – Vigilance Santé announces that, in February 2026, the company will roll out a major update to the Pregnancy and Breastfeeding content in its RxVigilance software. This update has been made possible in part through an agreement with Wolters Kluwer, the publisher of *Briggs, Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk* (hereafter “Briggs”). In addition to strengthening RxVigilance’s clinical value, this update is intended to support all health professionals in their decision-making when caring for this patient population.

“Our priority is to provide care teams with reliable, contextualized, and up-to-date clinical information, while simplifying access to essential reference points at the time of intervention. The revision of our Pregnancy and Breastfeeding content aligns directly with our commitment to facilitating excellence in medication therapy management,” said Pascale Lapointe, pharmacist and Product Director for RxVigilance and RxPhotos at Vigilance Santé.

Vigilance Santé’s added value: reliability, clarity, a French-language version, and up-to-date information

As a result of the agreement with Wolters Kluwer, RxVigilance now includes summaries based on content from Briggs, seamlessly integrated into clinical workflows. Professionals who wish to consult the full reference can purchase it directly from the publisher, Wolters Kluwer (link at the end of this release).

RxVigilance offers concise texts embedded within monographs to enable rapid consultation. Content derived from Briggs has also been translated into French to facilitate day-to-day use in Francophone settings. A disclaimer accompanies this translation, specifying that the publisher cannot be held responsible for it.

Finally, RxVigilance aims to provide the most up-to-date information possible. RxVigilance will continue to integrate relevant content rigorously, drawing on Briggs and other reliable sources used by Vigilance Santé to support clinical practice.

About Vigilance Santé

Vigilance Santé's mission is to facilitate excellence in medication therapy management. To this end, the company develops innovative and practical clinical tools that support healthcare professionals in delivering safe, evidence-based care. Renowned for its rigour, reliability, and continuous adaptation to the evolving needs of the industry, Vigilance Santé has earned a reputation as a trusted partner to healthcare professionals and organizations across Canada.

About Briggs

An essential tool for health professionals supporting pregnant or postpartum women, *Briggs, Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk* (12th edition), provides instant access to indispensable information on the topic. An easy A-to-Z format lists more than 1,400 of the most commonly prescribed drugs taken during pregnancy and lactation, with detailed monographs designed to provide the most essential information on possible effects on the mother, embryo, fetus, and nursing infant.

Purchase the book via Wolters Kluwer, here: <https://shop.lww.com/Briggs-Drugs-in-Pregnancy-and-Lactation/p/9781975162405>

– 30 –

For more information: 1-844-582-3917 or info@vigilance.ca

Follow Vigilance Santé on [Facebook](#) and [LinkedIn](#)